Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Moderate and Severe Inflammatory Acne Vulgaris Effectively Treated with Single-Agent Therapy by a New Fixed-Dose Combination Adapalene 0.3 %/Benzoyl Peroxide 2.5 % Gel: A Randomized, Double-Blind, Parallel-Group, Controlled Study

Open access
Stein Gold, Linda, Weiss, Jonathan, Rueda, Maria Jose, Liu, Hong, Tanghetti, Emil · 2016 · American Journal of Clinical Dermatology

Abstract

BACKGROUND: A need exists for topical treatments in managing more severe inflammatory acne. OBJECTIVES: The objectives of this study were to evaluate the efficacy and safety of adapalene 0.3 %/benzoyl peroxide 2.5 % (0.3 % A/BPO) topical gel in subjects with moderate and severe inflammatory acne. METHODS: This was a multicenter, randomized, double-blind, parallel-group study. Randomization was stratified by acne severity (50 % moderate and 50 % severe). Subjects received 0.3 % A/BPO, 0.1 % A/BPO (benchmark), or vehicle (comparator) once daily for 12 weeks. Co-primary efficacy endpoints were success rate at week 12 (the percentage of subjects rated 'clear' or 'almost clear' with at least a 2-grade improvement on Investigator's Global Assessment [IGA]) and change in inflammatory (IN) and noninflammatory (NIN) lesion counts from baseline to week 12. Secondary efficacy endpoints were percent changes in IN and NIN lesion counts. Safety endpoints were incidence of adverse events (AEs) and local tolerability signs/symptoms. RESULTS: A total of 503 subjects were randomized: 217, 217, and 69 subjects in the 0.3 % A/BPO, 0.1 % A/BPO, and vehicle groups, respectively. For success rate (subjects rated 'clear' or 'almost clear' with ≥2-grade improvement in IGA), 0.3 % A/BPO was superior to vehicle, with a treatment difference of 22.7 % (33.7 vs. 11.0 %; 95 % confidence interval [CI] 12.8-32.6, p < 0.001). At week 12, 0.3 % A/BPO was superior to vehicle for mean reduction from baseline in IN (27.0 vs. 14.4) and NIN lesion counts (40.2 vs. 18.5), as well as for percentage reduction from baseline in IN (68.7 vs. 39.2 %) and NIN lesion counts (68.3 vs. 37.4 %) (all p < 0.001). Among subjects with severe inflammatory acne (IGA = 4), 0.1 % A/BPO did not reach statistical significance for success rate compared with vehicle (p = 0.443), whereas 0.3 % A/BPO demonstrated significantly greater efficacy (p = 0.029, requiring ≥3-point IGA improvement). Additionally, 0.3 % A/BPO was safe and well-tolerated. CONCLUSIONS: Results of this clinical trial demonstrate the significantly greater efficacy of adapalene 0.3 % A/BPO topical gel compared with vehicle as well as a good safety profile in the treatment of moderate to severe inflammatory non-nodulocystic acne, which increases patients' treatment options. CLINICALTRIALS. GOV IDENTIFIER: NCT01880320.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40257-016-0178-4

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Investigator’s Global Assessment (IGA) scale
Fig. 1 Investigator’s Global Assessment (IGA) scaleCC BY-NC · PubMed Central
Fig. 2 Subject disposition. A adapalene, BPO benzoyl peroxide, ITT intent to treat, PP per protocol
Fig. 2 Subject disposition. A adapalene, BPO benzoyl peroxide, ITT intent to treat, PP per protocolCC BY-NC · PubMed Central
Fig. 3 Photographs of subject in 0.3 % A/BPO group with severe acne (IGA = 4) at (a) baseline, (b) week 1, and (c) week 12 with treatment success (IGA = 1, ‘almost clear’). A adapalene, BPO benzoyl peroxide, IGA Investigator’s Global Assessment
Fig. 3 Photographs of subject in 0.3 % A/BPO group with severe acne (IGA = 4) at (a) baseline, (b) week 1, and (c) week 12 with treatment success (IGA = 1, ‘almost clear’). A adapalene, BPO benzoyl peroxide, IGA Investigator’s Global AssessmentCC BY-NC · PubMed Central
Fig. 4 Photographs of subject in 0.3 % A/BPO group with severe acne (IGA = 4) at (a) baseline, (b) week 1, and (c) week 12 with treatment failure (IGA = 3, ‘moderate’). A adapalene, BPO benzoyl peroxide, IGA Investigator’s Global Assessment
Fig. 4 Photographs of subject in 0.3 % A/BPO group with severe acne (IGA = 4) at (a) baseline, (b) week 1, and (c) week 12 with treatment failure (IGA = 3, ‘moderate’). A adapalene, BPO benzoyl peroxide, IGA Investigator’s Global AssessmentCC BY-NC · PubMed Central
Fig. 5 Mean percent change (MI data; post hoc analysis performed prior to week 12) in (a) inflammatory lesions and (b) non-inflammatory lesions (ITT; MI). A adapalene, BPO benzoyl peroxide, ITT intent to treat, MI multiple imputation. *p < 0.05, **p < 0.001
Fig. 5 Mean percent change (MI data; post hoc analysis performed prior to week 12) in (a) inflammatory lesions and (b) non-inflammatory lesions (ITT; MI). A adapalene, BPO benzoyl peroxide, ITT intent to treat, MI multiple imputation. *p < 0.05, **p < 0.001CC BY-NC · PubMed Central
Fig. 6 Local tolerance parameters (safety population). A adapalene, BPO benzoyl peroxide, final last data observed during the post-baseline period for a subject, worst highest severity score observed during the post-baseline period for a subject
Fig. 6 Local tolerance parameters (safety population). A adapalene, BPO benzoyl peroxide, final last data observed during the post-baseline period for a subject, worst highest severity score observed during the post-baseline period for a subjectCC BY-NC · PubMed Central
Fig. 7 Subject’s assessment of acne improvement (week 12, intent-to-treat population). A adapalene, BPO benzoyl peroxide
Fig. 7 Subject’s assessment of acne improvement (week 12, intent-to-treat population). A adapalene, BPO benzoyl peroxideCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Research works printed but not linked: 1

  1. Vega B, Jomard A, Michel S. Regulation of human monocyte toll-like receptor 2 (TLR2) expression by adapalene. J Eur Acad Dermatol Venereol. 2002;16(Suppl 1):123–4.

Cited by

See all 61

Metadata

Authors
Stein Gold, L., Weiss, J., Rueda, M. J., Liu, H., & Tanghetti, E.
Affiliations
Center for Dermatology and Laser Surgery (US)
Venue
American Journal of Clinical Dermatology
Published
2016-03-05
Volume
17
Issue
3
Pages
293-303
ISSN
  • 1175-0561 (ISSN-L)
  • 1179-1888
OpenAlex
W2289204262
Cited by
61
References
26
Citations by year
2025: 8 · 2024: 10 · 2023: 7 · 2022: 4 · 2021: 7 · 2020: 7 · 2019: 7 · 2018: 5 · 2017: 4 · 2016: 2
FWCI
7.21
Type
journal article
Language
en
Open access
Locations
  • American Journal of Clinical Dermatology (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Galderma
Topics
  • Health Sciences › Medicine › Dermatology › Acne and Rosacea Treatments and Effects
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
  • Health Sciences › Medicine › Dermatology › Dermatologic Treatments and Research
Keywords
fixed-dose combination, adapalene, benzoyl peroxide, topical gel, acne lesion count, Investigator's Global Assessment, treatment efficacy, local tolerance, adverse events, monotherapy, vehicle comparison, dose comparison
MeSH terms
Adapalene, Acne Vulgaris, Administration, Cutaneous, Adolescent, Adult, Anti-Inflammatory Agents, Non-Steroidal, Benzoyl Peroxide, Child, Dermatologic Agents, Double-Blind Method, Drug Combinations, Female, Gels, Humans, Male, Middle Aged, Naphthalenes, Treatment Outcome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Moderate and Severe Inflammatory Acne Vulgaris Effectively Treated with Single-Agent Therapy by a New Fixed-Dose Combination Adapalene 0.3 %/Benzoyl Peroxide 2.5 % Gel: A Randomized, Double-Blind, Parallel-Group, Controlled Study. https://app.cochat.ai/papers/10.1007/s40257-016-0178-4
The paper
Stein Gold, L., Weiss, J., Rueda, M. J., Liu, H., & Tanghetti, E. (2016). Moderate and Severe Inflammatory Acne Vulgaris Effectively Treated with Single-Agent Therapy by a New Fixed-Dose Combination Adapalene 0.3 %/Benzoyl Peroxide 2.5 % Gel: A Randomized, Double-Blind, Parallel-Group, Controlled Study. American Journal of Clinical Dermatology. https://doi.org/10.1007/s40257-016-0178-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.